A recent review reveals that drugs designed to slow Alzheimer’s progression deliver no meaningful benefits to patients and elevate the risk of brain swelling and bleeding. Researchers analyzed data from multiple trials and found the treatments’ effects on early-stage Alzheimer’s and dementia patients to be absent or minimal.

Key Findings from the Comprehensive Analysis

The Cochrane review examined 17 studies involving 20,342 participants, primarily those with mild cognitive impairment, dementia, or both, aged 70 to 74 on average. It included trials of lecanemab and donanemab—currently licensed in the UK—as well as discontinued drugs like aducanumab, bapineuzumab, crenezumab, and solanezumab.

After 18 months, the drugs showed trivial impacts on cognitive function and dementia severity. Professor Edo Richard, a neurology expert at Radboud University Medical Centre in the Netherlands, noted that trial results over two decades remain inconsistent. He emphasized that the differences fall far below the threshold for noticeable effects on patients and caregivers.

Expert Views on Limited Efficacy

Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy, stated: “The evidence suggests these drugs make no meaningful difference to patients. There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect.”

Nonino highlighted the distinction between statistical significance in early trials and actual clinical relevance. He also pointed out that most studies cover only 18 months—a short period for a slowly progressing condition like Alzheimer’s—while real-world use could extend much longer.

Professor Richard, who manages a dementia clinic, shares candid assessments with patients. He informs them of the minimal benefits, burdensome requirements like frequent clinic visits for IV infusions, and necessary scans. “I think you will probably not benefit from these drugs, and they’re burdensome for you and your family,” he tells them. He stresses honesty to avoid false hope.

Potential Side Effects and Risks

The review identifies heightened risks of brain swelling and bleeding, detectable on scans but often asymptomatic. Long-term consequences remain unclear.

Charities Challenge the Conclusions

Dementia organizations dispute the review’s broad brushstroke approach, which combines failed older trials with recent successful ones for lecanemab and donanemab. Dr. Richard Oakley, associate director of research and innovation at the Alzheimer’s Society, said: “This review’s conclusions make the picture look bleaker than it really is… It’s essential that we interpret this review with nuance.”

Professor Jonathan Schott, neurology expert and group leader at the UK Dementia Research Institute at UCL, noted that pooling disparate studies—many ineffective against beta-amyloid—inevitably yields underwhelming group results.

Dr. Susan Kohlhaas, executive director of research at Alzheimer’s Research UK, added that even modest delays in decline offer valuable time for families. She cautioned against dismissing anti-amyloid treatments entirely, as research targets broader mechanisms.

Ongoing NICE Re-evaluation

The National Institute for Health and Care Excellence (NICE) previously rejected lecanemab and donanemab for NHS use due to insufficient benefits relative to costs. Now, NICE re-examines evidence following appeals by manufacturers Eli Lilly and Eisai, focusing on caregiver quality of life and NHS administration costs.